- Home
- AUTL vs CRGX Comparison
AUTL vs CRGX Comparison
Compare AUTL & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUTL
- CRGX
- Stock Information
- Founded
- AUTL 2014
- CRGX 2021
- Country
- AUTL United Kingdom
- CRGX United States
- Employees
- AUTL N/A
- CRGX N/A
- Industry
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- CRGX
- Sector
- AUTL Health Care
- CRGX
- Exchange
- AUTL Nasdaq
- CRGX Nasdaq
- Market Cap
- AUTL 590.8M
- CRGX 621.4M
- IPO Year
- AUTL 2018
- CRGX 2023
- Fundamental
- Price
- AUTL $2.37
- CRGX $13.46
- Analyst Decision
- AUTL Strong Buy
- CRGX Strong Buy
- Analyst Count
- AUTL 3
- CRGX 6
- Target Price
- AUTL $10.20
- CRGX $31.80
- AVG Volume (30 Days)
- AUTL 1.2M
- CRGX 231.3K
- Earning Date
- AUTL 03-13-2025
- CRGX 03-20-2025
- Dividend Yield
- AUTL N/A
- CRGX N/A
- EPS Growth
- AUTL N/A
- CRGX N/A
- EPS
- AUTL N/A
- CRGX N/A
- Revenue
- AUTL $10,091,000.00
- CRGX N/A
- Revenue This Year
- AUTL $851.83
- CRGX N/A
- Revenue Next Year
- AUTL $264.18
- CRGX N/A
- P/E Ratio
- AUTL N/A
- CRGX N/A
- Revenue Growth
- AUTL 82.71
- CRGX N/A
- 52 Week Low
- AUTL $2.07
- CRGX $10.91
- 52 Week High
- AUTL $7.37
- CRGX $33.92
- Technical
- Relative Strength Index (RSI)
- AUTL 46.88
- CRGX 47.00
- Support Level
- AUTL $2.12
- CRGX $12.51
- Resistance Level
- AUTL $2.38
- CRGX $15.75
- Average True Range (ATR)
- AUTL 0.13
- CRGX 1.09
- MACD
- AUTL 0.02
- CRGX 0.17
- Stochastic Oscillator
- AUTL 37.23
- CRGX 52.74
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.